Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Xie E, Yeo YH, Scheiner B, Zhang Y, Hiraoka A, Tantai X, Fessas P, de Castro T, D'Alessio A, Fulgenzi CAM, Xu S, Tsai HM, Kambhampati S, Wang W, Keenan BP, Gao X, Xing Z, Pinter M, Lin YJ, Guo Z, Vogel A, Tanaka T, Kuo HY, Kelley RK, Kudo M, Yang JD, Pinato DJ, Ji F. Xie E, et al. Among authors: scheiner b. JAMA Oncol. 2023 Oct 1;9(10):1423-1431. doi: 10.1001/jamaoncol.2023.3284. JAMA Oncol. 2023. PMID: 37615958 Free PMC article.
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.
Wu YL, van Hyfte G, Özbek U, Reincke M, Gampa A, Mohamed YI, Nishida N, Wietharn B, Amara S, Lee PC, Scheiner B, Balcar L, Pinter M, Vogel A, Weinmann A, Saeed A, Pillai A, Rimassa L, Naqash AR, Muzaffar M, Huang YH, Kaseb AO, Kudo M, Pinato DJ, Ang C. Wu YL, et al. Among authors: scheiner b. Front Oncol. 2023 Feb 14;13:1128569. doi: 10.3389/fonc.2023.1128569. eCollection 2023. Front Oncol. 2023. PMID: 36865801 Free PMC article.
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
Pinato DJ, Li X, Mishra-Kalyani P, D'Alessio A, Fulgenzi CAM, Scheiner B, Pinter M, Wei G, Schneider J, Rivera DR, Pazdur R, Theoret MR, Casak S, Lemery S, Fashoyin-Aje L, Cortellini A, Pelosof L. Pinato DJ, et al. Among authors: scheiner b. JHEP Rep. 2023 Mar 30;5(6):100747. doi: 10.1016/j.jhepr.2023.100747. eCollection 2023 Jun. JHEP Rep. 2023. PMID: 37197442 Free PMC article.
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Zeng Q, Klein C, Caruso S, Maille P, Allende DS, Mínguez B, Iavarone M, Ningarhari M, Casadei-Gardini A, Pedica F, Rimini M, Perbellini R, Boulagnon-Rombi C, Heurgué A, Maggioni M, Rela M, Vij M, Baulande S, Legoix P, Lameiras S; HCC-AI study group; Bruges L, Gnemmi V, Nault JC, Campani C, Rhee H, Park YN, Iñarrairaegui M, Garcia-Porrero G, Argemi J, Sangro B, D'Alessio A, Scheiner B, Pinato DJ, Pinter M, Paradis V, Beaufrère A, Peter S, Rimassa L, Di Tommaso L, Vogel A, Michalak S, Boursier J, Loménie N, Ziol M, Calderaro J. Zeng Q, et al. Among authors: scheiner b. Lancet Oncol. 2023 Dec;24(12):1411-1422. doi: 10.1016/S1470-2045(23)00468-0. Epub 2023 Nov 8. Lancet Oncol. 2023. PMID: 37951222
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma.
Dharmapuri S, Özbek U, Jethra H, Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota A, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, Kudo M, D'Alessio A, Rimassa L, Pinato DJ, Ang C. Dharmapuri S, et al. Among authors: scheiner b. World J Gastrointest Oncol. 2023 Nov 15;15(11):1900-1912. doi: 10.4251/wjgo.v15.i11.1900. World J Gastrointest Oncol. 2023. PMID: 38077640 Free PMC article.
The Hammersmith Score optimises patient selection and predicts for overall survival in early-phase cancer trial participants independent of tumour burden.
Korolewicz JA, Scheiner B, Fulgenzi CAM, D'Alessio A, Cortellini A, Pascual C, Mehan A, Partridge S, Gujral DM, Mohammed W, Mohammed O, Grzesiak A, Booker L, Cleator S, Pokrovska T, Saleem W, Rackie J, Needham Y, Krell J, McNeish I, Tookman L, Park WE, Asif M, Evans JS, Pinato DJ. Korolewicz JA, et al. Among authors: scheiner b. Chemotherapy. 2024 Apr 27. doi: 10.1159/000539109. Online ahead of print. Chemotherapy. 2024. PMID: 38679017
Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease.
Dominik N, Scheiner B, Zanetto A, Balcar L, Semmler G, Campello E, Schwarz M, Paternostro R, Simbrunner B, Hofer BS, Stättermayer AF, Pinter M, Trauner M, Quehenberger P, Simioni P, Reiberger T, Mandorfer M. Dominik N, et al. Among authors: scheiner b. Aliment Pharmacol Ther. 2024 Jun;59(11):1376-1386. doi: 10.1111/apt.17945. Epub 2024 Mar 14. Aliment Pharmacol Ther. 2024. PMID: 38482706
Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertension.
Semmler G, Hartl L, Mendoza YP, Simbrunner B, Jachs M, Balcar L, Schwarz M, Hofer BS, Fritz L, Schedlbauer A, Stopfer K, Neumayer D, Maurer J, Szymanski R, Meyer EL, Scheiner B, Quehenberger P, Trauner M, Aigner E, Berzigotti A, Reiberger T, Mandorfer M. Semmler G, et al. Among authors: scheiner b. Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000829. Online ahead of print. Hepatology. 2024. PMID: 38447034
165 results